GlobeNewswire by notified

Biotalys Awarded Multi-Year Grant to Develop New Biological Solutions for Cowpea and Other Legumes

Share

Ghent, BELGIUM, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Press release inside information

Biotalys Awarded Multi-Year Grant to Develop New Biological Solutions for Cowpea and Other Legumes

Company to receive $5.98million in total from the Bill & Melinda Gates Foundation to leverage its AGROBODY™ technology platform

Ghent, BELGIUM,and Research Triangle Park (NC), UNITED STATES20October2021, 07:00 CESTBiotalys (Euronext - BTLS), an Agricultural Technology (AgTech) company focused on addressing food protection challenges with protein-based biocontrol solutions, today announced it has been awarded a multi-year grant from the Bill & Melinda Gates Foundation to discover novel antifungal biocontrols for deployment to smallholder farmers. The project, identified as “Agrobodies for Crop Protection”, focuses on leveraging Biotalys’ AGROBODY Foundry™ technology platform to discover novel protein-based biofungicides with the ability to control Cercosporacanescens, the causative agent of leaf spot disease, an important devastating disease of cowpea and other legumes.

Cowpeas – often referred to as “black-eyed peas1 after one of its subspecies – are a subsistence crop, often intercropped with sorghum, maize and pearl millet, providing millions of mainly African farmers, many of whom are women, an affordable source of proteins. According to estimates, cowpeas are cultivated on 14.5 million hectares of land, have a worldwide production of 6.2 million tonnes and are consumed by over 200 million people on a daily basis.2 While the broad range of cowpea varieties has enabled to access more resistant varieties in certain growing regions, the impact of the leaf spot disease (Cercosporacanescens) can still decimate up to 40% of the production for smallholder growers.

During the course of the four-year project, Biotalys will receive a $5.98 million (€5.14 million) grant in non-refundable instalments to achieve, by the end of 2025, proof-of-concept of effective on planta protection of the cowpea crop from leaf spot by an AGROBODY™ bioactive with potential cross-efficacy against other Cercospora diseases (such as C. beticola) for broader application across different crops.

Patrice Sellès, CEO of Biotalys, stated: "We are delighted to receive this support from the Gates Foundation to apply our knowledge and technology to develop new biological solutions for the protection of cowpeas and other legumes, important subsistence crops for millions of smallholder farmers worldwide. Providing these growers with innovative and affordable tools to protect the yield and quality of their crops without compromising the health of their soils and the safety of their families creates an economical and societal benefit that cannot be achieved with existing chemical pesticides.”

This is an incredible opportunity for the Biotalys team to leverage the antifungal know-how that we have built with our AGROBODY Foundry™ platform while developing our current product pipeline,” saidInge Van Daele, Regulatory Head at Biotalys. “The scope of this new project goes beyond innovation and technology development. This work is about sustainability and making a difference to the lives and health of millions of smallholder farmers and we are proud to have been selected by the Gates Foundation to make an impactful contribution.”

The project is aligned with Biotalys’ strategy to become an agricultural technology leader by developing unique proprietary protein-based food protection solutions and addresses various Sustainable Development Goals set by the United Nations, such as Zero Hunger (SDG 2), Responsible Consumption and Production (SDG 12), and Life on Land (SDG 15).

About Biotalys

Biotalys is an Agricultural Technology (AgTech) company focused on addressing food protection challenges with proprietary protein-based biocontrol solutions and aiming to provide alternatives to conventional chemical pesticides for a more sustainable and safer food supply. Based on its novel AGROBODY™ technology platform, Biotalys has developed a strong and diverse pipeline of effective product candidates with a favorable safety profile that aim to address key crop pests and diseases across the whole value chain, from soil to plate. Biotalys was founded in 2013 as a spin-off from the VIB (Flanders Institute for Biotechnology) and is listed on Euronext Brussels since July 2021. The company is based in the biotech cluster in Ghent, Belgium. More information can be found on www.biotalys.com.

For further information, please contact:

Toon Musschoot, Head of Investor Relations & Communications
T: +32 (0)9 274 54 00
E: Toon.Musschoot@biotalys.com

ImportantNotice

This announcement contains statements which are "forward-looking statements" or could be considered as such. These forward-looking statements can be identified by the use of forward-looking terminology, including the words ‘aim’, 'believe', 'estimate', 'anticipate', 'expect', 'intend', 'may', 'will', 'plan', 'continue', 'ongoing', 'possible', 'predict', 'plans', 'target', 'seek', 'would' or 'should', and contain statements made by the company regarding the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are warned that none of these forward-looking statements offers any guarantee of future performance. The Biotalys actual results may differ materially from those predicted by the forward-looking statements. Biotalys makes no undertaking whatsoever to publish updates or adjustments to these forward-looking statements, unless required to do so by law.


1https://www.britannica.com/plant/cowpea

2 Kebede & Bekeko, (Cogent Food & Agriculture (2020), 6) and Food and Agriculture Organisation (http://www.fao.org/3/au994e/au994e.pdf).

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

CONDITIONS FOR SALE OF RIKSBANK CERTIFICATES30.11.2021 09:30:00 CET | Press release

Bid date, 2021-11-30Auction date2021-11-30Settlement date2021-12-01Maturity Date2021-12-08Nominal amount570 billion SEKInterest rate, %0.00Bid times09.30-10.00 (CET/CEST) on the Bid dateConfirmation of bids to e-mailrbcert@riksbank.seThe lowest accepted bid volume1 million SEKThe highest accepted bid volume570 billion SEKAllocation Time10.15 (CET/CEST) on the Bid dateProjected minimum liquidity surplus during the term1140 billion SEKExpected excess liquidity at full allotment570 billion SEK Stockholm, 2021-11-30

Stratio raises $12M Series A to Scale AI-based Predictive Fleet Maintenance Platform using Real-time Augmented Intelligence30.11.2021 09:02:00 CET | Press release

Investment led by Forestay with participation from existing investor Crane Venture Partners to be used to further accelerate global expansion, increase R&D, boost product development, and double headcount by the end of 2022 LISBON, Portugal and LONDON, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Stratio, the world’s leading real-time predictive fleet maintenance platform, today announced a $12M Series A funding round to further accelerate its growth. The investment, led by Forestay Capital, the Deep Tech and SaaS Venture Capital arm of Waypoint Capital, with participation from existing investor Crane Venture Partners, will be used to further accelerate the company’s global expansion, increase its R&D, speed up overall time-to-market, and double its headcount by the end of 2022. Stratio already has its technology deployed in 5 of the top 10 transportation companies in the world and has enabled transportation for 1.3 billion people so far. The company’s Annual Recurring Revenue (ARR) has grown 270

Not intended for U.S. Media – Solvay announces results of its tender offer to purchase bonds for cash30.11.2021 08:32:08 CET | Press release

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS), ANY STATE OF THE UNITED STATES OF AMERICA AND THE DISTRICT OF COLUMBIA OR TO ANY U.S. PERSON OR IN OR INTO ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT. Solvay SA continues its deleveraging through the early redemption of bonds due in 2022 Brussels, 30 November 2021 --- Solvay SA (the “Issuer”) today successfully closed the tender offer on its outstanding EUR 750 million 1.625% bonds due 2022, by acquiring €372.5 million of senior debt, marking another step in the strong deleveraging that commenced in 2019. As part of its G.R.O.W. strategy, Solvay has prioritised cash generation and, since January 2019, has generated €2.3 billion operationally, both from improving

Sampo plc’s share buybacks 29/11/202130.11.2021 08:30:00 CET | Press release

SAMPO PLC STOCK EXCHANGE RELEASE 30/11/2021 at 08:30 am Sampo plc’s share buybacks 29/11/2021 On 29/11/2021 Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI0009003305) as follows: Sampo plc’s share buybacksAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares*Market (MIC Code)33,86443.34AQEU34,08143.27CEUX4,67243.25TQEX109,28243.26XHELTOTAL181,89943.28 *rounded to two decimals On 1 October 2021, Sampo announced a share buyback programme of up to a maximum of EUR 750 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 4 October 2021, is based on the authorization granted by Sampo's Annual General Meeting on 19 May 2021. After the disclosed transactions, the company owns in total 5,631,827 Sampo A shares representing 1.01 per cent of the total number of shares in Sampo plc. Detai

Aino Health AB (publ): Världsledande tillverkare väljer Aino Healths SaaS-lösning HealthManager30.11.2021 08:30:00 CET | Pressemelding

Stockholm 30 November, 2021. Ett världsledande tillverkningsföretag och global marknadsledare inom aggregat-, mineralbearbetnings- och metallraffineringsindustrin har valt att utöka användningen av Aino Healths SaaS-lösning HealthManager. Avtalet innehåller totalt 2 400 licenser, varav 1 300 är nya licenser. "Vi är mycket glada och stolta över att fortsätta och utöka en nyckelaktör inom tillverkningsindustrin som kund. Vi ser fram emot att tillsammans öka personalens välbefinnande och engagemang", säger Jyrki Eklund, VD Aino Health. HealthManager är Ainos egen SaaS-lösning som stödjer chefer med interna hälsorelaterade processer och frånvarohantering. Det erbjuder också rapporterings- och analysverktyg för att följa viktiga mätvärden relaterade till företagets hälsohantering. Målet med lösningen är att digitalisera arbetsförmågasprocesser och öka medarbetarnas engagemang. Om Aino Health (publ) Aino Health är den ledande leverantören av Software as a Service-lösningar inom Corporate Hea

Aino Health AB (publ): World leading manufacturer chooses Aino Health's SaaS-solution HealthManager30.11.2021 08:30:00 CET | Press release

Stockholm 30 November, 2021. A world leading manufacturing company and global market leader for sustainable technologies in the aggregates, minerals processing and metals refining industries, has chosen to extend the usage of Aino Health’s SaaS-solution HealthManager. The agreement contains a total of 2 400 licenses, out of which 1 300 are new licenses. ”We are very happy and proud to continue and extend a key player in the manufacturing industry as a customer. We look forward to together increase their personnel’s’ wellbeing and engagement”, says Jyrki Eklund, CEO Aino Health. HealthManager is Ainos own SaaS solution that supports managers with internal health-related processes and absence management. It also offers reporting and analytic tools to follow key metrics related to corporate health management. The goal of the solution is to digitalize working ability processes and to increase employee engagement. About Aino Health (publ) Aino Health is the leading supplier of Software as a

PCI Biotech and Immunicum Announce an Extension to Their Research Collaboration to Explore Novel Cancer Vaccination Treatments30.11.2021 08:00:00 CET | Press release

Oslo, Norway, November 30, 2021 - PCI Biotech Holding ASA (OSE: PCIB), a cancer focused biopharmaceutical company with a unique intracellular delivery technology via Photochemical Internalisation and Immunicum AB (publ; IMMU.ST), a biopharmaceutical company focused on hard-to-treat established tumors and the prevention of cancer recurrence, announced today an extension of their current collaboration. The companies jointly research the possibility to overcome current hurdles in cancer immunotherapy by introducing tumor independent immune targets into the tumor microenvironment, in combination with vaccination or adoptive immunotherapies. The so-called Tumor Independent Antigen concept, which has been invented by Immunicum, could benefit from PCI Biotech’s antigen delivery technologies based on Photochemical Internalisation. Following the encouraging results of the first set of in vitro experiments, during which the delivery protocol of the combination treatment has been optimized, the c